摘要
目的通过检测柔红霉素(DNR)化疗后患者血浆N末端脑利钠肽原(NT-pro BNP)水平以评价DNR早期心肌毒性及参麦注射液对心脏的保护作用。方法将83例急性髓细胞白血病患者随机分为对照组和治疗组,均采用柔红霉素联合阿糖胞苷(DA)方案诱导化疗;治疗组另给予参麦注射液静脉滴注。观察治疗前后患者血浆NT-pro BNP水平、心肌酶谱(CK、CK-MB)和心电图(ECG)变化。结果治疗组中医证候疗效优于对照组(P<0.05)。治疗后,两组NT-pro BNP水平均显著上升(P<0.01),且两组之间有显著差异(P<0.05);两组治疗前后心肌酶含量变化不明显(P>0.05)。结论参麦注射液可降低柔红霉素化疗后患者血浆NT-proBNP水平以防治其心肌毒性。
Objective To evaluate the protective effect of ＂Shenmai Injection＂ on myocardiopathy by detecting the level of NT-pro BNP after treated by DNR. Methods Eighty-three cases were randonfized into control group and treatment group. The cases in control group were induced by induction chemotherapy of daunorubicin and DA protocol, and cases in treatment group were treated by induction chemotherapy and ＂Shenmai Injection＂. The NT-pro BNP level, changes of CK, CK-MB and ECG were observed before and after treatment. Results The TCM therapeutic effect in treatment group was better than that in the control group （P 〈0.05）. After treatment, the NT-pro BNP levels in both groups were elevated markedly （P 〈 0.01 ）, with a significant difference between the two groups （P 〈 0.05）. No significant changes of cardiac enzyme was found in both groups between before and after treatment （P 〉 0.05）. Conclusion ＂Shenmai Injection＂ can prevent and treat cardiac toxicity by lowering the NT-proBNP level after chemotherapy with daunorubicin.
出处
《上海中医药杂志》
2012年第8期47-49,共3页
Shanghai Journal of Traditional Chinese Medicine
基金
河北省廊坊市科技支撑计划项目(2010013124)
作者简介
[作者简介]孙长勇，男，硕士，主治医师，主要从事中西医结合治疗血液病研究工作。
